RANKL is a therapeutic target of bone destruction in rheumatoid arthritis [version 1; peer review: 2 approved]
Although remarkable advances have been made in the treatment of rheumatoid arthritis (RA), novel therapeutic options with different mechanisms of action and fewer side effects have been expected. Recent studies have demonstrated that bone-resorbing osteoclasts are critically involved in the bone des...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2019-04-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/8-533/v1 |